BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 36539515)

  • 1. Development and Validation of a Western Blot Method to Quantify Mini-Dystrophin in Human Skeletal Muscle Biopsies.
    Soderstrom CI; Larsen J; Owen C; Gifondorwa D; Beidler D; Yong FH; Conrad P; Neubert H; Moore SA; Hassanein M
    AAPS J; 2022 Dec; 25(1):12. PubMed ID: 36539515
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biochemical characterization of patients with in-frame or out-of-frame DMD deletions pertinent to exon 44 or 45 skipping.
    Anthony K; Arechavala-Gomeza V; Ricotti V; Torelli S; Feng L; Janghra N; Tasca G; Guglieri M; Barresi R; Armaroli A; Ferlini A; Bushby K; Straub V; Ricci E; Sewry C; Morgan J; Muntoni F
    JAMA Neurol; 2014 Jan; 71(1):32-40. PubMed ID: 24217213
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of capillary Western immunoassay (Wes) for quantification of dystrophin levels in skeletal muscle of healthy controls and individuals with Becker and Duchenne muscular dystrophy.
    Beekman C; Janson AA; Baghat A; van Deutekom JC; Datson NA
    PLoS One; 2018; 13(4):e0195850. PubMed ID: 29641567
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dystrophin and mini-dystrophin quantification by mass spectrometry in skeletal muscle for gene therapy development in Duchenne muscular dystrophy.
    Farrokhi V; Walsh J; Palandra J; Brodfuehrer J; Caiazzo T; Owens J; Binks M; Neelakantan S; Yong F; Dua P; Le Guiner C; Neubert H
    Gene Ther; 2022 Nov; 29(10-11):608-615. PubMed ID: 34737451
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low-level dystrophin expression attenuating the dystrophinopathy phenotype.
    Waldrop MA; Gumienny F; El Husayni S; Frank DE; Weiss RB; Flanigan KM
    Neuromuscul Disord; 2018 Feb; 28(2):116-121. PubMed ID: 29305136
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-Throughput Digital Image Analysis Reveals Distinct Patterns of Dystrophin Expression in Dystrophinopathy Patients.
    Torelli S; Scaglioni D; Sardone V; Ellis MJ; Domingos J; Jones A; Feng L; Chambers D; Eastwood DM; Leturcq F; Yaou RB; Urtizberea A; Sabouraud P; Barnerias C; Stojkovic T; Ricci E; Beuvin M; Bonne G; Sewry CA; Willis T; Kulshrestha R; Tasca G; Phadke R; Morgan JE; Muntoni F
    J Neuropathol Exp Neurol; 2021 Oct; 80(10):955-965. PubMed ID: 34498054
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Duchenne and Becker muscular dystrophy: a molecular and immunohistochemical approach.
    Freund AA; Scola RH; Arndt RC; Lorenzoni PJ; Kay CK; Werneck LC
    Arq Neuropsiquiatr; 2007 Mar; 65(1):73-6. PubMed ID: 17420831
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic polymorphism in muscle biopsies of Duchenne and Becker muscular dystrophy patients.
    Anand A; Prabhakar S; Kaul D
    Neurol India; 1999 Sep; 47(3):218-23. PubMed ID: 10514583
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correlation of Utrophin Levels with the Dystrophin Protein Complex and Muscle Fibre Regeneration in Duchenne and Becker Muscular Dystrophy Muscle Biopsies.
    Janghra N; Morgan JE; Sewry CA; Wilson FX; Davies KE; Muntoni F; Tinsley J
    PLoS One; 2016; 11(3):e0150818. PubMed ID: 26974331
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-Term Protective Effect of Human Dystrophin Expressing Chimeric (DEC) Cell Therapy on Amelioration of Function of Cardiac, Respiratory and Skeletal Muscles in Duchenne Muscular Dystrophy.
    Siemionow M; Langa P; Brodowska S; Kozlowska K; Zalants K; Budzynska K; Heydemann A
    Stem Cell Rev Rep; 2022 Dec; 18(8):2872-2892. PubMed ID: 35590083
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antisense Oligonucleotide Treatment in a Humanized Mouse Model of Duchenne Muscular Dystrophy and Highly Sensitive Detection of Dystrophin Using Western Blotting.
    Maruyama R; Yokota T
    Methods Mol Biol; 2021; 2224():203-214. PubMed ID: 33606217
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Large in-frame 5' deletions in DMD associated with mild Duchenne muscular dystrophy: Two case reports and a review of the literature.
    Gibbs EM; Barthélémy F; Douine ED; Hardiman NC; Shieh PB; Khanlou N; Crosbie RH; Nelson SF; Miceli MC
    Neuromuscul Disord; 2019 Nov; 29(11):863-873. PubMed ID: 31672265
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Severe cardiac involvement with preserved truncated dystrophin expression in Becker muscular dystrophy by +1G>A DMD splice-site mutation: a case report.
    Komaki R; Hashimoto Y; Mori-Yoshimura M; Oya Y; Takizawa H; Minami N; Nishino I; Aoki Y; Takahashi Y
    J Hum Genet; 2020 Oct; 65(10):903-909. PubMed ID: 32504006
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of Mini-Dystrophin on Dystrophin-Deficient, Human Skeletal Muscle-Derived Cells.
    Meng J; Counsell J; Morgan JE
    Int J Mol Sci; 2020 Sep; 21(19):. PubMed ID: 32998454
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel high-throughput immunofluorescence analysis method for quantifying dystrophin intensity in entire transverse sections of Duchenne muscular dystrophy muscle biopsy samples.
    Sardone V; Ellis M; Torelli S; Feng L; Chambers D; Eastwood D; Sewry C; Phadke R; Morgan JE; Muntoni F
    PLoS One; 2018; 13(3):e0194540. PubMed ID: 29579078
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel canine model for Duchenne muscular dystrophy (DMD): single nucleotide deletion in DMD gene exon 20.
    Mata López S; Hammond JJ; Rigsby MB; Balog-Alvarez CJ; Kornegay JN; Nghiem PP
    Skelet Muscle; 2018 May; 8(1):16. PubMed ID: 29843823
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Disease-proportional proteasomal degradation of missense dystrophins.
    Talsness DM; Belanto JJ; Ervasti JM
    Proc Natl Acad Sci U S A; 2015 Oct; 112(40):12414-9. PubMed ID: 26392559
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel point mutation affecting Asn76 of dystrophin protein leads to dystrophinopathy.
    Koczok K; Merő G; Szabó GP; Madar L; Gombos É; Ajzner É; Mótyán JA; Hortobágyi T; Balogh I
    Neuromuscul Disord; 2018 Feb; 28(2):129-136. PubMed ID: 29373175
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Causes of clinical variability in Duchenne and Becker muscular dystrophies and implications for exon skipping therapies.
    Hoffman EP
    Acta Myol; 2020 Dec; 39(4):179-186. PubMed ID: 33458572
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systemic deletion of
    Stirm M; Shashikadze B; Blutke A; Kemter E; Lange A; Stöckl JB; Jaudas F; Laane L; Kurome M; Keßler B; Zakhartchenko V; Bähr A; Klymiuk N; Nagashima H; Walter MC; Wurst W; Kupatt C; Fröhlich T; Wolf E
    Proc Natl Acad Sci U S A; 2023 Jul; 120(29):e2301250120. PubMed ID: 37428903
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.